-
Nursing federation demands proper pay, protection on Ebola front line
-
In wildfire town, PM says UK must 'face up to climate change'
-
France upholds assisted dying law, strikes down social media ban for children
-
In town hit by wildfire, PM says UK must 'face up to climate change'
-
Body found after wildfire hits Croatian coastal town
-
UK parliament probe into Farage resumes after polls win
-
Arteta expects Maresca to do an 'unbelievable job' at Man City
-
Italian police recover stolen Renoir, Cezanne and Matisse worth 9 mn euros
-
Stocks tread water with eyes on oil price
-
Prize money 'critical' for athletics, says Coe
-
US retail sales weakest in over a year in July
-
WHO decries lack of justice over 10,000 attacks on health care
-
Israel calls for police to replace military in handling West Bank settlers
-
SNC SCANDIC PAY: Betala – över hela världen och utan gränser
-
स्कैंडिक पे: दुनिया में कहीं भी, बिना किसी सीमा के भुगतान करें।
-
SNC SCANDIC ÍOC: Íoc in áit ar bith ar domhan, gan teorainn
-
SNC SCANDIC PAY: Platby po celém světě bez omezení
-
SNC SCANDIC PAY: Płatności na całym świecie bez ograniczeń
-
SNCスカンディックペイ):世界中で、制限なくお支払いいただけます
-
SNC 스칸딕 페이: 전 세계 어디서나, 제한 없이 결제하세요
-
斯堪迪克支付:全球無界支付
-
SNC SCANDIC PAY: الدفع في جميع أنحاء العالم ودون حدود
-
СНК СКАНДІК ПЕЙ: Оплата по всьому світу без обмежень
-
СНК Скандик Пэй: Оплата по всему миру без границ
-
SNC SCANDIC PAY: Pay anywhere in the world, without limits
-
Europe wildfires: latest developments
-
Maresca uncertain over Rodri's future at Man City
-
Hotter Europe isn't cooling investor fervor for stocks
-
MEXC's August 2026 Proof of Reserves Confirms User Assets Fully Backed as Reserve Ratios Remain Above 100%
-
Duplantis into pole vault final at Euros
-
Zambia suspends vote counting nationwide citing violence
-
Maresca says 'anything can happen' amid talk of Rodri move to Barcelona
-
Coe pledges court showing to defend World Athletics over Russia stance
-
Indonesian leader vows to shut over 750 'unproductive' state-owned firms
-
Stocks mixed as oil climbs, dollar drops
-
NATO jets shoot down drone in Latvian airspace: spokesperson
-
Tourists beat the heat with 'magical' Colosseum night tours
-
Wildfire forces hundreds to flee in western Germany
-
Spain extends largest nuclear plant in policy U-turn
-
Croatian wildfire forces thousands to flee, injures dozens
-
Gill says 'huge honour' to lead India in 600th Test
-
Latest developments: Europe battles wildfires
-
Brazilian police recover Matisse works stolen in 2025
-
Is a new conflict brewing in northern Ethiopia?
-
Exiled Putin critic says push for peace put him in danger
-
UK firefighters 'under pressure' as multiple blazes rage
-
EU to study potential vaccine for Lyme disease: companies
-
ARKBRIDGE Reaches 50,000 Clients and Launches New Referral Rewards Program
-
Colombia vows to find all missing quake victims as rescue hopes fade
-
New wildfire forces evacuation of 500 people in France
More Ebola trial vaccines arrive in Uganda
Uganda announced Thursday that it had received shipments of two more trial vaccines to test against a strain of Ebola responsible for dozens of deaths in the East African nation.
Since authorities declared an Ebola outbreak on September 20, Uganda has registered 142 confirmed cases and 56 deaths, but the spread has slowed in recent weeks, sparking hope that the epidemic could be on its way out.
The outbreak has been caused by the so-called Sudan strain of the virus, for which there is currently no vaccine.
But three candidate vaccines -- one developed by Oxford University and the Jenner Institute in Britain, another from the Sabin Vaccine Institute in the United States, and a third from the International AIDS Vaccine Initiative (IAVI) -- will be trialed in Uganda in the coming weeks.
On December 8, Uganda received its first shipment of doses from the Sabin Vaccine Institute.
"On Saturday December 17, we received two more candidate vaccines from Merck/IAVI of 2,160 doses and 2,000 doses from Oxford University/Jenner Institute manufactured by the Serum Institute of India," Health Minister Jane Ruth Aceng told a press briefing on Thursday.
They will be used in a so-called ring vaccination trial, where all contacts of confirmed Ebola patients, and contacts of contacts, are jabbed along with frontline and health workers.
Ugandan authorities said last month that new cases were falling, and the last confirmed patient with the disease was discharged from hospital on November 30.
The absence of active Ebola cases in recent days has held up the vaccine trials, according to international health experts working in Uganda.
Aceng said however that the authorities had already begun enlisting volunteers for the trials, adding that Uganda would take part in a global expert consultation meeting on Ebola on January 12.
The government last week lifted a two-month lockdown on two Ebola hotspots, removing curbs including a dusk-to-dawn curfew, a ban on personal travel and the closure of markets, bars and churches.
According to the World Health Organization (WHO), an outbreak of the disease ends when there are no new cases for 42 consecutive days -- twice the incubation period of Ebola.
Ebola spreads through bodily fluids. Common symptoms are fever, vomiting, bleeding and diarrhoea.
Outbreaks are difficult to contain, especially in urban environments.
A.AlHaj--SF-PST